A preliminary study on personalized treatment of locally advanced laryngeal cancer guided by MiniPDX models based on two patients
Objective Explore the use of the mini Patient-Derived Xenography(MiniPDX)to guide the newly-assisted therapy schemes of laryngeal cancer patients and laryngeal strategies.Methods Using the Oncovee® MiniPDX system developed by Shanghai Lidi Biotechnology Co.,Ltd.,the MiniPDX model is established with the specimen of laryngeal cancer patients as a prototype.Under the endoscopy,the laryngeal cancer tissue is performed by biopsy,and then the tumor cell suspension is prepared into the hollow fiber capsule,and the back of the Balb/C-NU nude mice is implanted under the skin to perform drug sensitivity tests.The best solution obtained from the MiniPDX measurement is used for local advanced laryngeal cancer for local chemotherapy and immunotherapy.Results From March 2022 to June 2023,we successfully constructed the MiniPDX model for two local advanced throat cancer patients,and established an individualized and sensitive drug screening system.The MiniPDX model has determined potential effective drugs for these two patients.Both patients have reached clinical relief after treatment.One of the patients reached CR(complete response),and the other patient's big pr(PARTIAL response).Neither of the two patients had serious adverse reactions,and both patients successfully retained laryngeal function.Conclusions Establishing a personalized drug screening system guided by the laryngeal cancer MiniPDX model may improve the clinical effect of patients,reduce ineffective treatments,and increase the laryngeal function retention rate of patients.
万方数据
